Jasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding Warrants
Key Highlights
- ➤Jasper Therapeutics (JSPR) offers $0.324 cash per outstanding warrant.
- ➤Offer targets 12,345,707 warrants, with approximately $4.0 million payable if fully tendered.
- ➤Warrants carry a $2.92 exercise price and expire March 18, 2030.
- ➤Tender offer closes one minute after 11:59 p.m. Eastern on November 6, 2026.
- ➤Retiring tendered warrants is intended to reduce potential share dilution and clarify capital structure.
REDWOOD CITY, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper” or the “Company”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today reported that it has commenced an offer to purchase (the "Offer") any and all of its outstanding warrants to purchase shares of its common stock, par value $0.0001 per share (the "Common Stock"), that were issued in its underwritten public offering on September 18, 2025 (the "Warrants"). The purchase price is $0.324 in cash per Warrant, without interest (the "Offer Purchase Price"). The purpose of the Offer is to reduce the number of shares of Common Stock that would become outstanding upon the exercise of the Warrants, thereby reducing the potential dilutive impact of the Warrants, and providing shareholders and prospective investors greater certainty as to the Company’s capital structure. Warrants tendered in the Offer will be retired and cancelled.
Get started
Create a free account to read the full story.